Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.50 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.50 |
| ▸ | TUBB | P07437 | 2/20 | 0.50 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.50 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.50 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.50 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.50 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.50 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.50 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.50 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.50 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.50 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.50 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.50 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8148063 | 0.90 | MEN1 (0.61) | MEN1KMT2ASMN1; SMN2TSHRMAPT | |
| SCHEMBL28097333 | 0.88 | TSHR (0.64) | MEN1KMT2ASMN1; SMN2TSHRMAPT | |
| SCHEMBL27578914 | 0.85 | LMNA (0.66) | MEN1KMT2ATSHRHTTLMNA | |
| SCHEMBL10887444 | 0.83 | MEN1 (0.54) | MEN1KMT2ASMN1; SMN2TSHRMAPT | |
| Methyl Syringate SCHEMBL211747 | 0.82 | MEN1 (0.61) | MEN1KMT2ASMN1; SMN2TSHRMAPT | |
| SCHEMBL6559151 | 0.81 | MAPT (0.59) | MEN1KMT2ASMN1; SMN2TSHRMAPT | |
| SCHEMBL10876059 | 0.81 | ABCG2 (0.53) | MEN1KMT2ASMN1; SMN2TSHRMAPT | |
| SCHEMBL28469235 | 0.81 | MEN1 (0.61) | MEN1KMT2ASMN1; SMN2TSHRMAPT | |
| SCHEMBL6939779 | 0.81 | KDM4E (0.40) | MEN1KMT2ASMN1; SMN2TSHRTPMT | |
| SCHEMBL8148066 | 0.80 | TSHR (0.59) | MEN1KMT2ASMN1; SMN2TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030008914-A1 | PHARMACEUTICAL FORMULATIONS USEFUL TO TREAT INFLAMMATORY AND IMMUNE DISORDERS | MILLENNIUM PHARMACEUTICALS, INC. | 2003-01-09 | — | — | US | disclosed |
| EP-1123095-A1 | PHARMACEUTICAL FORMULATIONS USEFUL TO TREAT INFLAMMATORY AND IMMUNE DISORDERS | Millennium Pharmaceuticals, Inc. (US) | 2001-08-16 | — | — | EP | disclosed |
| WO-2000023071-A9 | PHARMACEUTICAL FORMULATIONS USEFUL TO TREAT INFLAMMATORY AND IMMUNE DISORDERS | LEUKOSITE INC (US) | 2000-09-14 | — | — | WO | disclosed |
| WO-2000023071-A1 | PHARMACEUTICAL FORMULATIONS USEFUL TO TREAT INFLAMMATORY AND IMMUNE DISORDERS | LEUKOSITE, INC. (US) | 2000-04-27 | — | — | WO | disclosed |
| CN-1142495-A | Platelet activating factor antagonist and preparation thereof | MILLITARY MEDICAL UNIV NO 2 P (CN) | 1997-02-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008914-A1 | PHARMACEUTICAL FORMULATIONS USEFUL TO TREAT INFLAMMATORY AND IMMUNE DISORDERS | ALOX5, ALOX5AP, ALOX15 | MEN1 4464/4885KMT2A 2343/4885SMN1; SMN2 4553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.